Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide ... disease in adults with type 2 diabetes and chronic kidney disease. The Danish drugmaker said the approval ...

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

Novo Nordisk is pursuing new indications for semaglutide, including label expansions for Wegovy in additional cardiovascular conditions and for Ozempic in T2D patients with chronic kidney disease.

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names ...

Related Ozempic shows promise in treating fatty liver disease ... serious chronic diseases," Jorgensen said in a statement. The company said Friday that Jorgenson led Novo Nordisk through "a ...

Novo's Victoza and Ozempic ... chronic disease markets and the history of side effects from cardiometabolic drugs, but it has an immaterial effect on our valuation. We assign Novo Nordisk an ...

Share on Pinterest A Wegovy weight loss pill from Novo Nordisk is forthcoming ... “There is a shift to treating obesity as a chronic disease, like hypertension or diabetes, so patients may ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

Deboki: Ozempic is now a bona fide blockbuster. Novo Nordisk reported more than $40 ... clinical trials for treatment in heart, liver, and kidney conditions and a phase three trial for Alzheimers’ ...

The FDA has received reports of at least 20 cases of ileus, including two deaths, among people taking Ozempic. The agency ordered that the drugmaker, Novo Nordisk, add a warning label to the drug ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.